Nim, S, O'Hara, DM, Corbi-Verge, C, Perez-Riba, A, Fujisawa, K, Kapadia, M et al.. Disrupting the α-synuclein-ESCRT interaction with a peptide inhibitor mitigates neurodegeneration in preclinical models of Parkinson's disease. Nat Commun. 2023;14 (1):2150. doi: 10.1038/s41467-023-37464-2. PubMed PMID:37076542 PubMed Central PMC10115881.

McFarthing, K, Bloem, BR, Kalia, LV. People with Parkinson's as Partners for the Journal of Parkinson's Disease. J Parkinsons Dis. 2023;13 (2):125-126. doi: 10.3233/JPD-239000. PubMed PMID:36911950 PubMed Central PMC10041413.

Kalia, LV, Nimmo, GAM, Mestre, TA. Genetic Testing in Clinical Movement Disorders: A Case-Based Review. Semin Neurol. 2023;43 (1):147-155. doi: 10.1055/s-0043-1763507. PubMed PMID:36854393 .

Bloem, BR, Kalia, LV. The Journal of Parkinson's Disease Takes the Open Road. J Parkinsons Dis. 2023;13 (1):1-2. doi: 10.3233/JPD-229011. PubMed PMID:36744347 PubMed Central PMC9912718.

Bloem, BR, Kalia, LV. Thomas G. Beach, MD, PhD, FRCPC, Charles H. Adler, MD, PhD, FAAN, and Simon Stott, PhD, recipients of the Parkinson Prize 2022. J Parkinsons Dis. 2022;12 (8):2283-2286. doi: 10.3233/JPD-229010. PubMed PMID:36565068 .

Huang, Y, Meng, Y, Pople, CB, Bethune, A, Jones, RM, Abrahao, A et al.. Cavitation Feedback Control of Focused Ultrasound Blood-Brain Barrier Opening for Drug Delivery in Patients with Parkinson's Disease. Pharmaceutics. 2022;14 (12):. doi: 10.3390/pharmaceutics14122607. PubMed PMID:36559101 PubMed Central PMC9781334.

Fereshtehnejad, SM, Saleh, PA, Oliveira, LM, Patel, N, Bhowmick, S, Saranza, G et al.. Movement disorders in hereditary spastic paraplegia (HSP): a systematic review and individual participant data meta-analysis. Neurol Sci. 2023;44 (3):947-959. doi: 10.1007/s10072-022-06516-8. PubMed PMID:36441344 PubMed Central PMC9925593.

Kalia, LV. First trials test targeting of α-synuclein for Parkinson disease. Nat Rev Neurol. 2022;18 (12):703-704. doi: 10.1038/s41582-022-00726-6. PubMed PMID:36151474 .

Meng, Y, Pople, CB, Huang, Y, Jones, RM, Ottoy, J, Goubran, M et al.. Putaminal Recombinant Glucocerebrosidase Delivery with Magnetic Resonance-Guided Focused Ultrasound in Parkinson's Disease: A Phase I Study. Mov Disord. 2022;37 (10):2134-2139. doi: 10.1002/mds.29190. PubMed PMID:36089809 .

Ghadery, CM, Kalia, LV, Connolly, BS. Movement disorders of the mouth: a review of the common phenomenologies. J Neurol. 2022;269 (11):5812-5830. doi: 10.1007/s00415-022-11299-1. PubMed PMID:35904592 .

Kalia, LV, Bloem, BR. A New Chapter for the Journal of Parkinson's Disease. J Parkinsons Dis. 2022;12 (5):1365-1367. doi: 10.3233/JPD-229004. PubMed PMID:35811539 .

Sáenz-Farret, M, Lang, AE, Kalia, L, Cunha, I, Sousa, M, Kuhlman, G et al.. Spastic Paraplegia Type 7 and Movement Disorders: Beyond the Spastic Paraplegia. Mov Disord Clin Pract. 2022;9 (4):522-529. doi: 10.1002/mdc3.13437. PubMed PMID:35586535 PubMed Central PMC9092757.

Chen, KS, Menezes, K, Rodgers, JB, O'Hara, DM, Tran, N, Fujisawa, K et al.. Small molecule inhibitors of α-synuclein oligomers identified by targeting early dopamine-mediated motor impairment in C. elegans. Mol Neurodegener. 2021;16 (1):77. doi: 10.1186/s13024-021-00497-6. PubMed PMID:34772429 PubMed Central PMC8588601.

Oliveira, LM, Rastin, T, Nimmo, GAM, Ross, JP, Dion, PA, Zhang, M et al.. Occurrence of Amyotrophic Lateral Sclerosis in Type 1 Gaucher Disease. Neurol Genet. 2021;7 (4):e600. doi: 10.1212/NXG.0000000000000600. PubMed PMID:34017912 PubMed Central PMC8130998.

Barbuti, PA, Barker, RA, Brundin, P, Przedborski, S, Papa, SM, Kalia, LV et al.. Recent Advances in the Development of Stem-Cell-Derived Dopaminergic Neuronal Transplant Therapies for Parkinson's Disease. Mov Disord. 2021;36 (8):1772-1780. doi: 10.1002/mds.28628. PubMed PMID:33963552 .

O'Hara, DM, Kapadia, M, Ping, S, Kalia, SK, Kalia, LV. Semi-Quantitative Determination of Dopaminergic Neuron Density in the Substantia Nigra of Rodent Models using Automated Image Analysis. J Vis Exp. 2021; (168):. doi: 10.3791/62062. PubMed PMID:33616088 .

Bloem, BR, Trenkwalder, C, Sanchez-Ferro, A, Kalia, LV, Alcalay, R, Chiang, HL et al.. COVID-19 Vaccination for Persons with Parkinson's Disease: Light at the End of the Tunnel?. J Parkinsons Dis. 2021;11 (1):3-8. doi: 10.3233/JPD-212573. PubMed PMID:33523021 PubMed Central PMC7990445.

Branfield Day, L, Rajendram, P, Kalia, LV, Gold, WL. An Intelligent Diagnosis: SMART Syndrome. Am J Med. 2021;134 (7):863-865. doi: 10.1016/j.amjmed.2020.11.034. PubMed PMID:33444593 .

Saranza, G, Chen, KS, Ganos, C, Kalia, LV, Chen, R, Lang, AE et al.. Botulinum Toxin-Associated Prolonged Remission of Idiopathic Cervical Dystonia. Can J Neurol Sci. 2021;48 (6):864-868. doi: 10.1017/cjn.2020.280. PubMed PMID:33397526 .

Visanji, NP, Madan, P, Lacoste, AMB, Buleje, I, Han, Y, Spangler, S et al.. Using artificial intelligence to identify anti-hypertensives as possible disease modifying agents in Parkinson's disease. Pharmacoepidemiol Drug Saf. 2021;30 (2):201-209. doi: 10.1002/pds.5176. PubMed PMID:33219601 .

Mylvaganam, S, Earnshaw, R, Heymann, G, Kalia, SK, Kalia, LV. C-terminus of Hsp70 Interacting Protein (CHIP) and Neurodegeneration: Lessons from the Bench and Bedside. Curr Neuropharmacol. 2021;19 (7):1038-1068. doi: 10.2174/1570159X18666201116145507. PubMed PMID:33200713 PubMed Central PMC8686314.

Mukherjee, T, Ramaglia, V, Abdel-Nour, M, Bianchi, AA, Tsalikis, J, Chau, HN et al.. The eIF2α kinase HRI triggers the autophagic clearance of cytosolic protein aggregates. J Biol Chem. 2021;296 :100050. doi: 10.1074/jbc.RA120.014415. PubMed PMID:33168630 PubMed Central PMC7948985.

Kapadia, M, De Snoo, ML, Kalia, LV, Kalia, SK. Regulation of Parkin-dependent mitophagy by Bcl-2-associated athanogene (BAG) family members. Neural Regen Res. 2021;16 (4):684-685. doi: 10.4103/1673-5374.295330. PubMed PMID:33063725 PubMed Central PMC8067924.

Friesen, EL, Zhang, YT, Earnshaw, R, De Snoo, ML, O'Hara, DM, Agapova, V et al.. BAG5 Promotes Alpha-Synuclein Oligomer Formation and Functionally Interacts With the Autophagy Adaptor Protein p62. Front Cell Dev Biol. 2020;8 :716. doi: 10.3389/fcell.2020.00716. PubMed PMID:32850835 PubMed Central PMC7417480.

Meng, Y, Pople, CB, Kalia, SK, Kalia, LV, Davidson, B, Bigioni, L et al.. Cost-effectiveness analysis of MR-guided focused ultrasound thalamotomy for tremor-dominant Parkinson's disease. J Neurosurg. 2020; :1-6. doi: 10.3171/2020.5.JNS20692. PubMed PMID:32764177 .

O'Hara, DM, Pawar, G, Kalia, SK, Kalia, LV. LRRK2 and α-Synuclein: Distinct or Synergistic Players in Parkinson's Disease?. Front Neurosci. 2020;14 :577. doi: 10.3389/fnins.2020.00577. PubMed PMID:32625052 PubMed Central PMC7311858.

Fomenko, A, Lee, DJ, McKinnon, C, Lee, EJ, de Snoo, ML, Gondard, E et al.. Deep Brain Stimulation of the Medial Septal Nucleus Induces Expression of a Virally Delivered Reporter Gene in Dentate Gyrus. Front Neurosci. 2020;14 :463. doi: 10.3389/fnins.2020.00463. PubMed PMID:32477058 PubMed Central PMC7235415.

Maclagan, LC, Visanji, NP, Cheng, Y, Tadrous, M, Lacoste, AMB, Kalia, LV et al.. Identifying drugs with disease-modifying potential in Parkinson's disease using artificial intelligence and pharmacoepidemiology. Pharmacoepidemiol Drug Saf. 2020;29 (8):864-872. doi: 10.1002/pds.5015. PubMed PMID:32410265 .

O'Hara, DM, Kalia, SK, Kalia, LV. Methods for detecting toxic α-synuclein species as a biomarker for Parkinson's disease. Crit Rev Clin Lab Sci. 2020;57 (5):291-307. doi: 10.1080/10408363.2019.1711359. PubMed PMID:32116096 .

Espay, AJ, Kalia, LV, Gan-Or, Z, Williams-Gray, CH, Bedard, PL, Rowe, SM et al.. Disease modification and biomarker development in Parkinson disease: Revision or reconstruction?. Neurology. 2020;94 (11):481-494. doi: 10.1212/WNL.0000000000009107. PubMed PMID:32102975 PubMed Central PMC7220234.

McKinnon, C, De Snoo, ML, Gondard, E, Neudorfer, C, Chau, H, Ngana, SG et al.. Early-onset impairment of the ubiquitin-proteasome system in dopaminergic neurons caused by α-synuclein. Acta Neuropathol Commun. 2020;8 (1):17. doi: 10.1186/s40478-020-0894-0. PubMed PMID:32059750 PubMed Central PMC7023783.

De Snoo, ML, Friesen, EL, Zhang, YT, Earnshaw, R, Dorval, G, Kapadia, M et al.. Bcl-2-associated athanogene 5 (BAG5) regulates Parkin-dependent mitophagy and cell death. Cell Death Dis. 2019;10 (12):907. doi: 10.1038/s41419-019-2132-x. PubMed PMID:31787745 PubMed Central PMC6885512.

Kalia, LV. Expert comment: "A case of missing pathology in a patient with LRRK2 Parkinson's disease". Parkinsonism Relat Disord. 2020;74 :78-79. doi: 10.1016/j.parkreldis.2019.11.005. PubMed PMID:31727562 .

Kalia, LV, Jellinger, KA. Multiple system atrophy and myoclonus: A morphologic marker in the spinal cord?. Neurology. 2019;93 (7):287-288. doi: 10.1212/WNL.0000000000007941. PubMed PMID:31405931 .

Rajalingam, R, Breen, DP, Chen, R, Fox, S, Kalia, LV, Munhoz, RP et al.. The clinical significance of lower limb tremors. Parkinsonism Relat Disord. 2019;65 :165-171. doi: 10.1016/j.parkreldis.2019.06.007. PubMed PMID:31201091 .

McKinnon, C, Gros, P, Lee, DJ, Hamani, C, Lozano, AM, Kalia, LV et al.. Deep brain stimulation: potential for neuroprotection. Ann Clin Transl Neurol. 2019;6 (1):174-185. doi: 10.1002/acn3.682. PubMed PMID:30656196 PubMed Central PMC6331208.

Kalia, LV. Diagnostic biomarkers for Parkinson's disease: focus on α-synuclein in cerebrospinal fluid. Parkinsonism Relat Disord. 2019;59 :21-25. doi: 10.1016/j.parkreldis.2018.11.016. PubMed PMID:30466800 .

Picillo, M, Lizarraga, KJ, Friesen, EL, Chau, H, Zhang, M, Sato, C et al.. Parkinsonism due to A53E α-synuclein gene mutation: Clinical, genetic, epigenetic, and biochemical features. Mov Disord. 2018;33 (12):1950-1955. doi: 10.1002/mds.27506. PubMed PMID:30423204 .

Coakeley, S, Ang, LC, Jansen, GH, Cho, SS, Lang, AE, Houle, S et al.. [18 F]AV-1451 binding and postmortem pathology of CBD. Mov Disord. 2018;33 (8):1360-1361. doi: 10.1002/mds.27356. PubMed PMID:30136331 .

Ruskey, JA, Zhou, S, Santiago, R, Franche, LA, Alam, A, Roncière, L et al.. The GBA p.Trp378Gly mutation is a probable French-Canadian founder mutation causing Gaucher disease and synucleinopathies. Clin Genet. 2018;94 (3-4):339-345. doi: 10.1111/cge.13405. PubMed PMID:29920646 .

O'Hara, DM, Kalia, SK, Kalia, LV. Emerging disease-modifying strategies targeting α-synuclein for the treatment of Parkinson's disease. Br J Pharmacol. 2018;175 (15):3080-3089. doi: 10.1111/bph.14345. PubMed PMID:29722028 PubMed Central PMC6031880.

Meng, Y, Voisin, MR, Suppiah, S, Kalia, SK, Kalia, LV, Hamani, C et al.. Is there a role for MR-guided focused ultrasound in Parkinson's disease?. Mov Disord. 2018;33 (4):575-579. doi: 10.1002/mds.27308. PubMed PMID:29476631 .

Baskin, B, Kalia, LV, Banwell, BL, Ray, PN, Yoon, G. Complex genomic rearrangement in SPG11 due to a DNA replication-based mechanism. Mov Disord. 2017;32 (12):1792-1794. doi: 10.1002/mds.27188. PubMed PMID:29082553 .

Friesen, EL, De Snoo, ML, Rajendran, L, Kalia, LV, Kalia, SK. Chaperone-Based Therapies for Disease Modification in Parkinson's Disease. Parkinsons Dis. 2017;2017 :5015307. doi: 10.1155/2017/5015307. PubMed PMID:28913005 PubMed Central PMC5585656.

Park, S, Bin, NR, Yu, B, Wong, R, Sitarska, E, Sugita, K et al.. UNC-18 and Tomosyn Antagonistically Control Synaptic Vesicle Priming Downstream of UNC-13 in Caenorhabditis elegans. J Neurosci. 2017;37 (36):8797-8815. doi: 10.1523/JNEUROSCI.0338-17.2017. PubMed PMID:28821673 PubMed Central PMC5588468.

Kalia, LV. Biomarkers for cognitive dysfunction in Parkinson's disease. Parkinsonism Relat Disord. 2018;46 Suppl 1 :S19-S23. doi: 10.1016/j.parkreldis.2017.07.023. PubMed PMID:28781202 .

Koprich, JB, Kalia, LV, Brotchie, JM. Animal models of α-synucleinopathy for Parkinson disease drug development. Nat Rev Neurosci. 2017;18 (9):515-529. doi: 10.1038/nrn.2017.75. PubMed PMID:28747776 .

Rosborough, K, Patel, N, Kalia, LV. α-Synuclein and Parkinsonism: Updates and Future Perspectives. Curr Neurol Neurosci Rep. 2017;17 (4):31. doi: 10.1007/s11910-017-0737-y. PubMed PMID:28324300 .

Breen, DP, Kalia, LV. Exploiting the aggregation properties of alpha-synuclein for diagnostic purposes. Mov Disord. 2017;32 (1):106. doi: 10.1002/mds.26884. PubMed PMID:27896833 .

Visanji, NP, Brotchie, JM, Kalia, LV, Koprich, JB, Tandon, A, Watts, JC et al.. α-Synuclein-Based Animal Models of Parkinson's Disease: Challenges and Opportunities in a New Era. Trends Neurosci. 2016;39 (11):750-762. doi: 10.1016/j.tins.2016.09.003. PubMed PMID:27776749 .

Rowland, NC, Kalia, SK, Kalia, LV, Larson, PS, Lim, DA, Bankiewicz, KS et al.. Merging DBS with viral vector or stem cell implantation: "hybrid" stereotactic surgery as an evolution in the surgical treatment of Parkinson's disease. Mol Ther Methods Clin Dev. 2016;3 :15051. doi: 10.1038/mtm.2015.51. PubMed PMID:26817024 PubMed Central PMC4714520.

Kalia, LV, Lang, AE. Parkinson disease in 2015: Evolving basic, pathological and clinical concepts in PD. Nat Rev Neurol. 2016;12 (2):65-6. doi: 10.1038/nrneurol.2015.249. PubMed PMID:26782330 .

Kalia, LV, Kalia, SK, Lang, AE. Disease-modifying strategies for Parkinson's disease. Mov Disord. 2015;30 (11):1442-50. doi: 10.1002/mds.26354. PubMed PMID:26208210 .

Kalia, LV, Kalia, SK. α-Synuclein and Lewy pathology in Parkinson's disease. Curr Opin Neurol. 2015;28 (4):375-81. doi: 10.1097/WCO.0000000000000215. PubMed PMID:26110807 .

Kalia, LV, Lang, AE. Parkinson's disease. Lancet. 2015;386 (9996):896-912. doi: 10.1016/S0140-6736(14)61393-3. PubMed PMID:25904081 .

Shah, BB, Chen, R, Zurowski, M, Kalia, LV, Gunraj, C, Lang, AE et al.. Repetitive transcranial magnetic stimulation plus standardized suggestion of benefit for functional movement disorders: an open label case series. Parkinsonism Relat Disord. 2015;21 (4):407-12. doi: 10.1016/j.parkreldis.2015.01.013. PubMed PMID:25737204 .

Kalia, LV, Lang, AE, Hazrati, LN, Fujioka, S, Wszolek, ZK, Dickson, DW et al.. Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease. JAMA Neurol. 2015;72 (1):100-5. doi: 10.1001/jamaneurol.2014.2704. PubMed PMID:25401511 PubMed Central PMC4399368.

Kalia, LV, Rockman-Greenberg, C, Borys, A, Lang, AE. Tremor in Spinocerebellar Ataxia Type 12. Mov Disord Clin Pract. 2014;1 (1):76-78. doi: 10.1002/mdc3.12015. PubMed PMID:30363887 PubMed Central PMC6183183.

Beilina, A, Rudenko, IN, Kaganovich, A, Civiero, L, Chau, H, Kalia, SK et al.. Unbiased screen for interactors of leucine-rich repeat kinase 2 supports a common pathway for sporadic and familial Parkinson disease. Proc Natl Acad Sci U S A. 2014;111 (7):2626-31. doi: 10.1073/pnas.1318306111. PubMed PMID:24510904 PubMed Central PMC3932908.

Dimant, H, Kalia, SK, Kalia, LV, Zhu, LN, Kibuuka, L, Ebrahimi-Fakhari, D et al.. Direct detection of alpha synuclein oligomers in vivo. Acta Neuropathol Commun. 2013;1 :6. doi: 10.1186/2051-5960-1-6. PubMed PMID:24252244 PubMed Central PMC3776213.

Kalia, LV, Lang, AE, Aviv, RI, Masellis, M. Author response. Neurology. 2013;81 (13):1181. . PubMed PMID:24191352 .

AlDakheel, A, Kalia, LV, Lang, AE. Pathogenesis-targeted, disease-modifying therapies in Parkinson disease. Neurotherapeutics. 2014;11 (1):6-23. doi: 10.1007/s13311-013-0218-1. PubMed PMID:24085420 PubMed Central PMC3899477.

Civardi, C, Collini, A, Kalia, LV, Lang, AE, Aviv, RI, Masellis, M et al.. Hemichorea-hemiballism associated with hyperglycemia and a developmental venous anomaly. Neurology. 2013;81 (13):1181. doi: 10.1212/WNL.0b013e3182a7a945. PubMed PMID:24062343 .

Kalia, LV, Kalia, SK, McLean, PJ, Lozano, AM, Lang, AE. α-Synuclein oligomers and clinical implications for Parkinson disease. Ann Neurol. 2013;73 (2):155-69. doi: 10.1002/ana.23746. PubMed PMID:23225525 PubMed Central PMC3608838.

Kalia, LV, Brotchie, JM, Fox, SH. Novel nondopaminergic targets for motor features of Parkinson's disease: review of recent trials. Mov Disord. 2013;28 (2):131-44. doi: 10.1002/mds.25273. PubMed PMID:23225267 .

Kalia, LV, Mozessohn, L, Aviv, RI, da Costa, L, Lang, AE, Shadowitz, S et al.. Hemichorea-hemiballism associated with hyperglycemia and a developmental venous anomaly. Neurology. 2012;78 (11):838-9. doi: 10.1212/WNL.0b013e318249f733. PubMed PMID:22411959 PubMed Central PMC3304947.

Pitcher, GM, Kalia, LV, Ng, D, Goodfellow, NM, Yee, KT, Lambe, EK et al.. Schizophrenia susceptibility pathway neuregulin 1-ErbB4 suppresses Src upregulation of NMDA receptors. Nat Med. 2011;17 (4):470-8. doi: 10.1038/nm.2315. PubMed PMID:21441918 PubMed Central PMC3264662.

Kalia, LV, Kalia, SK, Chau, H, Lozano, AM, Hyman, BT, McLean, PJ et al.. Ubiquitinylation of α-synuclein by carboxyl terminus Hsp70-interacting protein (CHIP) is regulated by Bcl-2-associated athanogene 5 (BAG5). PLoS One. 2011;6 (2):e14695. doi: 10.1371/journal.pone.0014695. PubMed PMID:21358815 PubMed Central PMC3040167.

Kalia, SK, Kalia, LV, McLean, PJ. Molecular chaperones as rational drug targets for Parkinson's disease therapeutics. CNS Neurol Disord Drug Targets. 2010;9 (6):741-53. doi: 10.2174/187152710793237386. PubMed PMID:20942788 PubMed Central PMC3364514.

Kalia, LV, Lee, L, Kalia, SK, Pirouzmand, F, Rapoport, MJ, Aviv, RI et al.. Thoracic myelopathy from coincident fluorosis and epidural lipomatosis. Can J Neurol Sci. 2010;37 (2):276-8. doi: 10.1017/s0317167100010076. PubMed PMID:20437944 .

Ng, D, Pitcher, GM, Szilard, RK, Sertié, A, Kanisek, M, Clapcote, SJ et al.. Neto1 is a novel CUB-domain NMDA receptor-interacting protein required for synaptic plasticity and learning. PLoS Biol. 2009;7 (2):e41. doi: 10.1371/journal.pbio.1000041. PubMed PMID:19243221 PubMed Central PMC2652390.

Kalia, LV, Kalia, SK, Salter, MW. NMDA receptors in clinical neurology: excitatory times ahead. Lancet Neurol. 2008;7 (8):742-55. doi: 10.1016/S1474-4422(08)70165-0. PubMed PMID:18635022 PubMed Central PMC3589564.

Kalia, LV, Pitcher, GM, Pelkey, KA, Salter, MW. PSD-95 is a negative regulator of the tyrosine kinase Src in the NMDA receptor complex. EMBO J. 2006;25 (20):4971-82. doi: 10.1038/sj.emboj.7601342. PubMed PMID:16990796 PubMed Central PMC1618112.

Kalia, LV, O'Connor, PW. Severity of chronic pain and its relationship to quality of life in multiple sclerosis. Mult Scler. 2005;11 (3):322-7. doi: 10.1191/1352458505ms1168oa. PubMed PMID:15957515 .

Kalia, LV, Gingrich, JR, Salter, MW. Src in synaptic transmission and plasticity. Oncogene. 2004;23 (48):8007-16. doi: 10.1038/sj.onc.1208158. PubMed PMID:15489918 .

Salter, MW, Kalia, LV. Src kinases: a hub for NMDA receptor regulation. Nat Rev Neurosci. 2004;5 (4):317-28. doi: 10.1038/nrn1368. PubMed PMID:15034556 .

Kalia, LV, Salter, MW. Interactions between Src family protein tyrosine kinases and PSD-95. Neuropharmacology. 2003;45 (6):720-8. doi: 10.1016/s0028-3908(03)00313-7. PubMed PMID:14529711 .

Fam, SR, Gallagher, CJ, Kalia, LV, Salter, MW. Differential frequency dependence of P2Y1- and P2Y2- mediated Ca 2+ signaling in astrocytes. J Neurosci. 2003;23 (11):4437-44. doi: 10.1523/JNEUROSCI.23-11-04437.2003. PubMed PMID:12805284 PubMed Central PMC6740798.

Kalia, LV. Barriers to women clinician-scientists: a trainee's perspective. Clin Invest Med. 2003;26 (1):15-6. . PubMed PMID:12659464 .

Nong, Y, Huang, YQ, Ju, W, Kalia, LV, Ahmadian, G, Wang, YT et al.. Glycine binding primes NMDA receptor internalization. Nature. 2003;422 (6929):302-7. doi: 10.1038/nature01497. PubMed PMID:12646920 .

Pelkey, KA, Askalan, R, Paul, S, Kalia, LV, Nguyen, TH, Pitcher, GM et al.. Tyrosine phosphatase STEP is a tonic brake on induction of long-term potentiation. Neuron. 2002;34 (1):127-38. doi: 10.1016/s0896-6273(02)00633-5. PubMed PMID:11931747 .

Regan, D, Hajdur, LV, Hong, XH. Two-dimensional aspect ratio discrimination for shape defined by orientation texture. Vision Res. 1996;36 (22):3695-702. doi: 10.1016/0042-6989(96)00083-1. PubMed PMID:8976999 .

Search PubMed